Please login to the form below

Not currently logged in
Email:
Password:

cancer immunotherapies

This page shows the latest cancer immunotherapies news and features for those working in and with pharma, biotech and healthcare.

AZ withdraws Imfinzi in the US for advanced bladder cancer after post-marketing study fail

AZ withdraws Imfinzi in the US for advanced bladder cancer after post-marketing study fail

Despite the withdrawal, AZ still has several phase 3 trials testing Imfinzi in various treatment combinations for early- and late-stage bladder cancer. ... NMIBC). A number of immunotherapies are approved for bladder cancer, including Merck &Co/MSD’s

Latest news

More from news
Approximately 22 fully matching, plus 100 partially matching documents found.

Latest Intelligence

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    and ovarian cancer, and some tumours such as pancreatic and prostate cancers have proved resistant to current immunotherapies. ... Precision cancer treatment. The shift towards immunotherapies has been accompanied by another key trend – targeting

  • Deal Watch January 2018

    Back in June 2015 Celgene and Juno announced a ten-year collaboration to combine their respective immunology expertise to develop new immunotherapies for cancer and autoimmune diseases based on T cell ... The incoming cash will be used by Immunomedics to

  • Deal Watch November 2015 Deal Watch November 2015

    A package deal covering up to five cancer immunotherapies, the headline value was $1.56bn with an upfront fee of $60m; the subsequent milestone terms per product could reach in excess ... Sanofi will gain access to BioNTech's mRNA formulation technology

  • Pharma deals in June 2015 Pharma deals in June 2015

    Immune modulators in cancer and beyond. Both Juno Therapeutics and Celgene have had a busy month in forming alliances in the immunotherapy area. ... Near the close of the month, Juno and Celgene announced a $1bn, 10-year collaboration to develop novel

  • Medius Deal Watch table for March 2015 Medius Deal Watch table for March 2015

    Phase 3 immuno-oncology treatment for prostate cancer. 975. Intrexon / Merck Serono. ... 825. Aduro / Novartis. Licence and collaboration. Preclinical cancer immunotherapies targeting the STING (Stimulator of Interferon Genes) pathway.

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest appointments

  • BMS appoints new commercial leader, Davies joins Eisai and more BMS appoints new commercial leader, Davies joins Eisai and more

    Gaweco will lead Apeiron’s immuno-oncology programmes, overseeing the discovery, clinical and medical functions of the company’s new molecular entities pipeline of cancer immunotherapies. ... His outreach into the worldwide pharmaceutical markets

  • Targovax strengthens board of directors Targovax strengthens board of directors

    of our novel and complementary portfolio of cancer immunotherapies.”.

  • BMS’ Dr Mike Burgees joins Turnstone Biologics BMS’ Dr Mike Burgees joins Turnstone Biologics

    He said: “ Turnstone Biologics is uniquely positioned to deliver breakthrough viral-based immunotherapies for patients with cancer. ... Mike’s oncology expertise will be instrumental in advancing the development of our next-generation viral

  • Merck’s Richard Murray joins Jounce as CEO Merck’s Richard Murray joins Jounce as CEO

    pembrolizumab. This experience will benefit Jounce, a Cambridge, Massachusetts-based company that specialises in cancer immunotherapies. ... The new CEO sees potential in Jounce, however, with the prospect of cancer immunotherapies an appetising one for

  • Bruno Strigini leaves Merck & Co for Novartis Bruno Strigini leaves Merck & Co for Novartis

    These sales made Novartis the third largest pharma company in cancer for the year. ... The area of anti-PD1 cancer immunotherapies looks to be an important one for many companies, with Bristol-Myers Squibb, Roche and AstraZeneca all developing their own

More from appointments
Approximately 1 fully matching, plus 7 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 2 fully matching, plus 4 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Havas Life Medicom

We’re a specialist-led, unified communications agency delivering connected healthcare communications, informed through fresh insights, smart thinking and inspired ideas. Our...

Latest intelligence

Article:
The disparity of patient experiences with Crohn’s Disease in Europe and Japan...
Patient diversity in clinical trials
The pursuit of patient diversity in clinical trials
When all-inclusive isn’t an option, it’s an obligation...
Overcoming the digital patient recruitment challenges of connecting with patients
How many irrelevant experiences, ads, emails, direct messages have you rejected this week?...